HIV/AIDS Topics HIV Treatment Conferences IAS 2015
IAS 2015: Bone Loss Slows, but Continues Long-term in HIV-positive People on Antiretroviral Therapy
- Details
- Category: Bone Loss
- Published on Wednesday, 09 September 2015 00:00
- Written by Liz Highleyman
People with HIV experienced a decrease in bone density at the hip and spine during their first 2 years after starting antiretroviral therapy (ART). While bone loss slowed after 96 weeks, it continued to decline more rapidly among HIV-positive people compared with the usual age-related bone loss seen in HIV-negative people over 7 years, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
IAS 2015: The TPP and Access to HIV and HCV Treatment [VIDEO]
- Details
- Category: HIV Policy & Advocacy
- Published on Wednesday, 09 September 2015 00:00
- Written by Gregory Fowler
The Trans-Pacific Partnership trade agreement, now under consideration, will heavily impact the availability of medications for HIV and viral hepatitis, both in middle-income countries and in high-income countries such as Canada that rely on generic drugs, advocates said at a Médecins Sans Frontières media briefing at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
IAS 2015: Rilpivirine + Darunavir HIV Maintenance Regimen Matches Standard 3-Drug ART
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 08 September 2015 00:00
- Written by Liz Highleyman
A NRTI-sparing dual antiretroviral regimen consisting of the NNRTI rilpivirine (Edurant) plus the boosted HIV protease inhibitor darunavir (Prezista) maintained viral suppression and was well-tolerated by people who switched from a standard 3-drug regimen, according to results from the PROBE study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
Half of U.S. Gay Men Using Dating Apps Have Interacted with a PrEP User
- Details
- Category: Treatment as Prevention
- Published on Wednesday, 09 September 2015 00:00
- Written by Roger Pebody
Almost half of American gay men recruited to participate in a survey via advertising on a major mobile phone dating app say that at least one potential sexual partner has said that he was taking HIV pre-exposure prophylaxis (PrEP), and even more have interacted with someone who said that he was HIV-positive but had an undetectable viral load. Many of these potential partners were looking for sex without a condom, according to the survey results, published in the August 21 online edition ofJournal of Acquired Immune Deficiency Syndromes.
IAS 2015: Many People with Long-term HIV Infection Do Not Achieve Full CD4 Cell Recovery
- Details
- Category: HIV Disease Progression
- Published on Wednesday, 02 September 2015 00:00
- Written by Liz Highleyman
One-third of people who started combination antiretroviral therapy (ART) many years ago using first-generation protease inhibitors did not achieve complete immunological recovery with normal CD4 T-cell counts despite good viral suppression, according to a French study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.
IAS 2015: Peer-Led Intervention Lowers HIV Infections Among Drug Injectors in Ukraine
- Details
- Category: Injection Drug Use
- Published on Tuesday, 08 September 2015 00:00
- Written by Roger Pebody
A cluster-randomized trial in Ukraine has shown that a peer education project reduced new HIV infections in people who inject drugs by 41%, researchers reported at the recent 8th Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
IAS 2015: Gay Men Are Using Nuanced Sero-adaptive Behaviors to Prevent HIV Infection
- Details
- Category: HIV Sexual Transmission
- Published on Wednesday, 02 September 2015 00:00
- Written by Roger Pebody
There is evidence that some groups of Australian and American gay men are considering HIV-positive partners’ undetectable viral load and the time elapsed since an HIV-negative partner last tested when making decisions about using condoms, according to studies presented at the recent 8th International AIDS Society Conference in Vancouver.
More Articles...
- IAS 2015: PrEP Adherence, Sexual Behavior, and HIV and STI Incidence [VIDEO]
- IAS 2015: Peer or Community Interventions Improve Outcomes for Mothers with HIV
- IAS 2015: HIV+ People with Asymptomatic Cognitive Impairment More Likely to Develop Symptoms
- IAS 2015: Estrogen May Block HIV Reactivation, Hints at Gender Differences in Viral Reservoirs
- IAS 2015: ADAPT Study Shows PrEP Feasibility [VIDEO]
- IAS 2015: Fatty Liver May Contribute to Higher Risk of Death for HIV/HCV Coinfected People
- IAS 2015: Accessing Hepatitis C Treatment [VIDEO]
- IAS 2015: Information about HIV Treatment as Prevention Lessens Stigma and Increases Testing
- IAS 2015: HIV Treatment Scale-up Linked to Reduced Mortality Among Vancouver Drug Injectors
- IAS 2015: HIV+ Youth Are Less Likely than Adults to Achieve Viral Suppression on ART
- IAS 2015: Broadly Neutralizing Antibodies Against HIV [VIDEO]
- IAS 2015: First Brazilian Data Reinforce Evidence that PrEP is Mostly Used by Those at Greatest Risk
- IAS 2015: Innovative Linkage to Care Approaches Boost Clinic Visits, HIV Treatment Uptake in African Study
- IAS 2015: HIV Self-Testing May Help "Hard to Reach" Learn Their Status, but Uncertainties Remain
- IAS 2015: Ryan and Julie Lewis -- The 30/30 Project [VIDEO]
- IAS 2015: HIV and Hepatitis B Coinfected People Can Safely Switch to Simpler TAF Single-Tablet Regimen
- IAS 2015: PrEP and the Risk of Hepatitis C Virus Infection [VIDEO]
- Updated Guidelines for Pregnant Women with HIV and Preventing Mother-to-Child Transmission
- IAS 2015: High Adherence and No HIV Infections Seen in Heterosexual PrEP Study in Botswana
- IAS 2015: Implant and Injectable Hormonal Contraception Most Effective Methods for Women with HIV
- IAS 2015: A Community Perspective on HIV Prevention Science [VIDEO]
- IAS 2015: Altered Cholesterol Metabolism May Protect Immune Cells of Non-Progressors
- IAS 2015: Indiana HIV Outbreak -- Lessons about Containing Local Outbreaks and Harm Reduction
- IAS 2015: START Supports ART For All [VIDEO]
- IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV
- IAS 2015: Daclatasvir + Sofosbuvir Cures Most Coinfected People in French Compassionate Use Study
- IAS 2015: Pros and Cons of PrEP -- Volunteers Recount their Experiences in ADAPT Study
- IAS 2015: Intensification of ART Reduces Risk of Late-term Mother-to-Child HIV Transmission
- IAS 2015: Young Gay Men at Lower Risk for HIV than Previous Generations, but Racial Disparities Persist
- IAS 2015: Zinc Finger Nuclease Genome Editing [VIDEO]
- IAS 2015: People with Hepatitis B Can Safely Use Truvada PrEP for HIV Prevention
- IAS 2015: Cash to Stay in School Didn't Reduce HIV Incidence, but Attendance Protects Young Women
- IAS 2015: Cash Encourages Circumcision, Prevention of Mother-to-Child HIV Transmission
- IAS 2015: Targets Proliferate in HIV Cure Research
- IAS 2015: Interferon-free Hepatitis Treatment Highly Effective for HIV/HCV Coinfected People
- IAS 2015: Vancouver's HIV Treatment as Prevention Success Also Due to Harm Reduction
- IAS 2015: Gay Youth PrEP Study Finds Good Retention and Reasonable Adherence
- IAS 2015: Fibrosis Regression Linked to Reduced Complications and Death in HIV/HCV Coinfected
- IAS 2015: U.S. PrEP Demo Project Finds People at Highest HIV Risk Take PrEP Most Consistently
- IAS 2015: Treatment Cascades Show 90-90-90 Goals Reachable, Eastern Europe Lags Behind Africa
- IAS 2015: Test and Treat Studies and African Country Experience Show 90-90-90 Targets Are Achievable
- IAS 2015: Switching to Tenofovir Alafenamide Keeps HIV Suppressed, Helps Kidneys and Bones
- IAS 2015: Raltegravir Prevents Mother-to-Child HIV Transmission During Late Pregnancy
- IAS 2015: Same-day Antiretroviral Treatment Leads to Faster HIV Suppression in San Francisco
- IAS 2015: Intermittent PrEP May Be Robust Strategy for Anal Sex -- Vaginal Protection Less Certain
- IAS 2015: WHO Urges More HIV Testing Outside Clinical Settings, Targeting Those Who Need It Most
- IAS 2015: Presumptive Treatment of TB in Advanced HIV No Better than ART and Isoniazid
- IAS 2015: New NNRTI Doravirine Suppresses HIV as Well as Efavirenz But with Fewer CNS Side Effects
- IAS 2015: No HIV Infections from Partners with Fully Suppressed Virus in Landmark Trial
- IAS 2015: Opioid Substitution Therapy Combined with HIV Treatment Saves More Lives
- IAS 2015: Young Woman Stays Undetectable for 12 Years Off Treatment After Early HIV Therapy
- IAS 2015: Non-Daily PrEP Provides Extra Options, But Adherence Often Better with Daily Dosing
- IAS 2015: Vancouver Consensus Calls for Early Access to HIV Treatment and PrEP Worldwide
- IAS 2015: Maturation Inhibitor BMS-955176 Shows Good Antiviral Activity with Atazanavir
- IAS 2015: START Trial Provides Definitive Evidence of Benefits of Early HIV Treatment
- IAS 2015: Access to Screening and Treatment Are Key Issues for Hepatitis B and C
- IAS 2015: A New Era of HIV Treatment and Prevention [VIDEO]
- IAS 2015: World Health Organization to Recommend HIV Treatment for All
- Coverage of the 2015 International AIDS Society Conference
Web Design and Development by